Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Keytruda
Pharma
Keytruda's novel head and neck cancer nod comes with a limit
For the breakthrough perioperative head and neck cancer indication, Keytruda is only allowed in patients with PD-L1-positive tumors.
Angus Liu
Jun 13, 2025 10:50am
FDA limits Keytruda, Opdivo uses in stomach cancer
Jun 9, 2025 10:50am
Gilead bolsters Trodelvy with first-line breast cancer win
May 31, 2025 8:00am
Gilead's Trodelvy chalks up another phase 3 breast cancer win
May 23, 2025 10:10am
AZ, Merck duke it out to lead oncologists’ pharma perceptions
May 22, 2025 10:54am
Keytruda delivers trial win in some patients with ovarian cancer
May 15, 2025 10:56am
